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One of the most basic characteristics of cancer cells is the
loss of cell-cell adhesion and acquirement of invasive prop-
erties. During cancer progression, the regulation and expres-
sion of cell-cell adhesion molecules (like cadherins) play a
pivotal role. In most invasive tumors, E-cadherin is downre-
gulated and N-cadherin is de novo expressed (known as
epithelial-to-mesenchymal transition). However, in some
invasive carcinomas, E-cadherin expression is maintained,
with the concomitant de novo expression of another cad-
herin – P-cadherin. Their co-expression occurs frequently
in breast carcinomas, which show a worst patient prognosis
when compared with patients harboring tumors with loss of
E-cadherin as single event. In the last ten years, our group
has been mainly interested in understanding the role of P-
cadherin overexpression in cancer cells, as well as the gene
regulatory mechanisms behind its aberrant expression.
P-cadherin has been extensively studied concerning its
function and prognostic value in breast cancer. Its over-
expression has been identified in 30% of invasive carci-
nomas, being highly associated with proliferative lesions
of high histological grade and decreased patient survival.
Recently, we showed that P-cadherin overexpression
confers an invasive capacity to breast cancer cells, indu-
cing the secretion of MMPs, which are responsible by
the cleavage of its extracellular domain, giving rise to a
P-cadherin soluble form. We proved that this fragment
is a pro-invasive factor, which needs to be inhibited to
render cancer cells non-invasive.
Still, we identified the intracellular signaling pathway
that regulates and activates the P-cadherin (CDH3) gene
promoter, inducing P-cadherin overexpression in breast
cancer cells. We found that an antiestrogen is able to
increase CDH3 promoter activity, as well as to induce
activating histone epigenetic modifications at putative
C/EBPb binding sites in the CDH3 gene promoter. We
showed, for the first time, that C/EBPb is able to regu-
late P-cadherin overexpression.
Furthermore, our recent data supports the idea that
P-cadherin has a role in cancer stem cell biology. We found
that breast cancer cell lines, presenting the highest levels of
P-cadherin, show the highest expression of the stem cell
markers CD49f, CD44 and CD24, as well as ALDH1 activity.
Importantly, we reproduced these results in primary tumors,
where we found that P-cadherin overexpression occurs in
breast carcinomas with a cancer stem cell phenotype
(CD44
+CD24
-/low) and ALDH1 expression. These results are
now being experimentally addressed by mammosphere, 2D
and 3D culture in vitro assays, to be then confirmed in vivo.
In conclusion, our results open new avenues in breast
cancer treatment, since P-cadherin is likely to be a good
therapeutic target for invasive carcinomas overexpres-
sing this protein. Scientifically, our studies will help to
understand better the pathogenesis of breast cancer and
other cancer models involving cadherin’s alterations.
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